[Fundamental and clinical studies on T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
Fundamental and clinical studies were made on T-1982 (cefbuperazone) and the results were obtained as follows. Serum and uterine tissue concentrations of T-1982 were determined at 26 minutes before and at 20 to 80 minutes after the completion of intravenous drip infusion of 1 g. The levels of T-1982 in the fallopian tube, ovarium, endometrium, myometrium and uterine cervix were 23.7, 19.5, 50.5, 10.9 micrograms/g and 17.5 micrograms/g at 20 minutes after the completion of infusion. The levels were sufficiently effective against major pathogens (Gram negative bacteria and anaerobic bacilli) isolated in the field of obstetrics and gynecology. T-1982 was administered to 11 patients, including 7 of acute adnexitis, each one of pelveoperitonitis, pyometra, puerperal fever, and 1 of puerperal fever with sepsis, at a dose of 1-2 g twice a day for a period of 5 to 9 days by intravenous injection or intravenous drip infusion. Clinical responses were excellent in 5, good in 3 and poor in 3. No adverse reactions nor marked changes in laboratory findings were observed in any of the cases treated with T-1982.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002513:Cephamycins / Q000032:analysis* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010053:Ovary / Q000032:analysis* / Q000098:blood supply; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy; D014599:Uterus / Q000032:analysis*
D002513:Cephamycins; C035978:cefbuperazone